Cancer immunotherapy in 2026: a crash course
A sourced crash course on cancer immunotherapy in 2026: checkpoint inhibitors, CAR-T, bispecifics, mRNA cancer vaccines and the solid-tumour frontier.
Cancer immunotherapy
CAR-T, checkpoint inhibitors, cancer vaccines and other ways of turning the immune system on tumours.
Cancer immunotherapy tracker: approvals and trial results
A dated, sourced timeline of cancer immunotherapy milestones from 2024 to October 2026: approvals, phase 3 readouts, safety actions and setbacks.
Antibody-drug conjugates (ADCs)
Bispecific antibodies and T-cell engagers
CAR-T cell therapy
Immune checkpoint inhibitors
In vivo CAR-T
Personalised mRNA neoantigen vaccines
Tumour-infiltrating lymphocyte (TIL) therapy
Can immunotherapy crack solid tumours? The 2026 debate
How cancer vaccines work, from shared antigens to personalised mRNA
How CAR-T cell therapy works
How the immune system fights cancer, and how tumours escape